A competition radioimmunoassay was developed, utilizing a murine monoclonal antibody to human pancreatic adenocarcinoma cells. Immunoblotting of a standard antigen preparation from either serum or ascites fluid after electrophoresis in 1% agarose showed that the specific DU-PAN-2 activity resided in two major high molecular weight bands. DU-PAN-2 antigen levels were expressed as arbitrary units based on a standard partially purified antigen preparation. The inhibition curve with standard antigen was reproducible (SD < 10%) and essentially linear from 25 to 200 units/ml. The mean DU-PAN-2 antigen concentration for the sera from 126 normal individuals was 81 units/mi. Sera from pediatric patients with malignancy had a mean of 127 units/ml, while nasopharyngeal, stage III melanoma, and ovarian carcinoma patients had means of 89, 92, and 119 units/mi, respectively. All values in normal subjects as well as the melanoma, nasoplaryngeal, ovarian, and pediatric cancer patients were Wiss than 400 units/mi. Intermediate antigen levels were detected in patients with alimentary tract malignancies. Eight of 20 gastric cancer and 8 of 76 colorectal carcinoma patients and 3 patients with benign or nonmalig nant gastrointestinal tract disease had DU-PAN-2 values exceeding 400 units/ml. Ascites fluids from 6/6 and pancreatic juice from 2/2 pancreatic cancer patients had values greater than 750 units/ml. Serum from 68% of the 89 pancreatic cancer patients tested had DU-PAN-2 antigen levels greater than 400 units/ml. The mean serum value in this patient population was 4888 units/mi.
toring pancreatic cancer could enhance treatment of the disease. We have produced a monoclonal antibody to pancreatic adenocarcinoma that might provide such a tool.
We have previously reported on the production and partial serological characterization of five monoclonal antibodies elicited to the human pancreatic adenocarcinoma cell line HPAF (3) . One of these monoclonal antibodies, DU-PAN-2, detects an antigen present on some cells of fetal pancreas and on ductal epithelial cells of normal adult pancreas, as well as on adenocarcinoma cells of pancreatic and nonpancreatic origin (3, 4) . Recent studies of the tissue distribution of this antigen indicated that the antigen is probably a secretory cell product. Although DU-PAN-2 antigen is not a tumor-specific marker, there is a marked difference in the level of expression of the antigen on neoplastic tissues compared to analogous nonneoplastic structures (4) . Preliminary studies on the molecular properties of the DU-PAN-2 antigen suggest that the epitope is sensitive to neuraminidase and is expressed on a large, heavily glycosylated molecule (ref. 5 and unpublished data) . In this report, we describe the electrophoretic properties of the DU-PAN-2 antigen and its identification by immunoblotting. A competition radioimmunoassay (RIA) for the antigen was also developed, using the DU-PAN-2 IgM monoclonal antibody. This report describes the use of this competition RIA to detect and monitor the levels of DU-PAN-2 antigen in serum and ascites of patients with various malignant and nonmalignant diseases.
MATERIALS AND METHODS
DU-PAN-2 Antigen. The DU-PAN-2 antigen used as target antigen for the RIA and as a standard antigen for the inhibition curves was prepared from ascites of a patient with pancreatic adenocarcinoma. An immunoaffinity column could not be used for antigen purification because the DU-PAN-2 IgM antibody shows poor antigen binding when coupled to an insoluble matrix. Therefore, the antigen was partially purified by other techniques. A 50-75% saturated ammonium sulfate fraction of the ascitic fluid contained >95% of the DU-PAN-2 antigen. Since human serum albumin in the ascites fluid precipitated with DU-PAN-2 antigen in the 50-75% saturated ammonium sulfate fraction, material from that fraction was dialyzed against 20 mM sodium phosphate, pH 7.1, and chromatographed on a Cibacron blue F3G-A-Sepharose CL-6B column to remove albumin. More than 90% of the DU-PAN-2 antigen was eluted within one bed volume, while 90% or more of the albumin was removed. The antigen preparation recovered from the Cibacron blue F3G-A-Sepharose CL-6B column was then treated with 1.0 M perchloric acid for 15 min in an ice bath, centrifuged at 15,000 x g for 5 min, decanted, neutralized, and dialyzed overnight against phosphate-buffered saline.
For electrophoretic and immunoblot analysis, DU-PAN-2 antigen was also purified by cesium bromide density gradient centrifugation (6) V, overnight in the cold. The sheet was then incubated with 5% bovine serum albumin at 40°C followed by DU-PAN-2 antibody or a control antibody at room temperature for 1 hr with continuous rocking. After washing, the paper was incubated for 1 hr with rabbit antibody to mouse IgM, followed by 1-hr incubation with 125I-labeled staphyloccal protein A at 106 cpm/ml. The blots were again extensively washed, blotted dry, and exposed to Kodak X AR-5 x-ray film with an intensifying screen at -70°C for 1 hr.
Clinical Samples. Serum, plasma, and ascites samples were obtained from normal volunteers and patients with malignant and nonmalignant disease. Some of the samples were obtained directly from the patient and then tested before freezing, while other samples, often from the serum banks of collaborating investigators, were tested after freezing. The samples from pediatric patients with lymphomas or solid tumors were obtained from Dr. Barry Dowell, Texas Childrens Hospital, Houston; the sera from nasopharyngeal carcinoma patients were from Dr. T. C. Lynn, National Taiwan University Hospital, Taipei; and the sera from ovarian cancer patients was obtained from Dr. Stanley Gall, Department of Obstetrics-Gynecology, Duke University Medical Center, Durham, NC.
RESULTS
Immunoblot of DU-PAN-2 Antigen. We have analyzed the binding reactivity of DU-PAN-2 antibody with soluble antigen preparations from ascitic fluid and serum of pancreatic adenocarcinoma patients. Both preparations were partially purified, subjected to electrophoresis in 1% agarose, and immunoblotted as described in Materials and Methods.
The DU-PAN-2 antibody gave similar patterns of reactivity with the antigen preparations from both serum (Fig. 1 , lane B) and ascites fluid (Fig. 1, lane C) . Two prominent bands were seen with each antigen and the apparently higher molecular weight bands from both sources migrated to the same positions on the gels. The lower molecular weight band from serum migrated slower and was less intense than that from ascites. An IgM monoclonal antibody to a human myeloid cell antigen failed to detect bands in these regions (Fig. 1 , lane A) in either preparation.
RIA. Rather than express the results as percent inhibition and titer, we express the quantity of DU-PAN-2 antigen in a sample as arbitrary units/ml based on reference to the partially purified standard antigen sample (see Materials and Methods). The amount of DU-PAN-2 antigen in 20 1l of a 1:500 dilution of the standard antigen preparation was dasignated as 100 units/ml. As shown in Fig. 2 , a semilogarithmic plot of the percent inhibition vs. DU-PAN-2 antigen concentration is essentially linear over the range of 20-70% inhibition and could therefore be used as a standard curve for calculating antigen concentration in an unknown sample. The standard deviations ranged from 9.8% at 25 units/ml to 6.5% at 200 units/ml and were calculated from the mean of 13-21 determinations for each point. Each of these determinations was done on different testing dates over a 2-to 3-month period. Thus, the between-assay variability for the standard antigen preparation was 10% or less. Purified carcinoembryonic antigen, ABO, and Lewis blood group antigens gave less than 5% inhibition in the RIA. Body fluid samples being tested for DU-PAN-2 antigen were then titered by 1:1 dilutions and units/ml were calculated from the dilution giving between 30% and 70% inhibition.
Partially purified DU-PAN-2 antigen was stable at 100'C for more than 15 min and there has been no loss of DU-PAN-2 antigen activity in the standard antigen preparation stored at -20'C for over 1 year. Sera from patients with high levels of DU-PAN-2 antigen and sera from normal donors have not A B C shown any marked changes in DU-PAN-2 units after storage at -20TC for 6 months. Patients' sera stored longer than 2 years at -20'C still had high levels of DU-PAN-2 antigen when tested.
Detection of DU-PAN-2 Antigen in Ascites and Cyst Fluids. Ascites fluid from the patient from whom the HPAF cell line was derived was used as the source of the standard antigen.
The untreated and perchloric acid-extracted ascites fluid from this patient contained more than 50,000 units/ml, whereas ascites fluid from a patient with chronic renal failure had less than 10 units/ml. Ascites or cyst fluid samples were not tested at less than a 1:4 dilution. All of the ascites fluids from patients with pancreatic adenocarcinoma had 750 or more units/ml, whereas ascites fluid from one patient with chronic renal failure and three patients with leukemia or lymphoma had <10 units/ml (Table 1) . Patients with other types of solid tumors gave intermediate levels ranging from <100 units/ml to 1000 units/ml. Fluid aspirated from pseudocysts from two patients with pancreatitis had <50 units/ml, whereas fluid from a patient with a mucinous cyst adenocarcinoma of the pancreas had >100,000 units/ml. Fluid from the pancreatic duct of two pancreatic adenocarcinoma patients was taken at the time of surgical resection and was found to have 2400 and 5200 units/ml. Pancreatic duct fluid from a patient with a nongastrointestinal tract malignancy had only 83 DU-PAN-2 units/ml.
Detection of DU-PAN-2 Antigen in Serum. Sera from normal volunteers, from patients with a variety of malignant diseases, and from patients with pancreatitis were titered in the competition RIA; the DU-PAN-2 units/ml were calculated and expressed in a dot chart (Fig. 3) 10 ,000 and 100,000 units/ml (shown as >7000 in Fig. 3) . Some of the pancreatic adenocarcinoma patients reported in Fig. 3 AP, alkaline phosphatase; ND, not done. Alkaline phosphatase is expressed as international units/ml; bilirubin is mg/dl. elevated DU-PAN-2 antigen in June 1982. The patient expired in July 1982, when DU-PAN-2 antigen was 1216 units/ml. There was a poor correlation in this patient between bilirubin/alkaline phosphatase levels and DU-PAN-2 antigen levels. DISCUSSION Agarose gel electrophoresis followed by immunoblotting (Fig. 1) provides a means of assessing the molecular properties of the DU-PAN-2 antigen, the nature of the antigenic determinant, and a method for determining the relationship of DU-PAN-2 to other tumor-associated antigens with similar properties. The highly glycosylated nature of DU-PAN-2 molecules and their behavior on gels and density gradients allows for their separation from many proteins and glycoproteins. More detailed studies on the molecular properties of the DU-PAN-2 antigen will be reported separately. However, we did want to provide the reader of this report with some visual data on the DU-PAN-2 antigen.
The competition RIA, as described in this report, appears to be a rapid and sensitive assay for fluids containing molecules with the DU-PAN-2 epitope. inhibition in the competition RIA. Although the reason for this inhibition is still unknown, there are striking quantitative differences in the levels of inhibition by normal donor sera and those from pancreatic cancer patients. This difference became apparent when the concentration of DU-PAN-2 antigen was expressed in arbitrary units. We were unable to adapt the DU-PAN-2 monoclonal antibody to a radioimmunometric type assay because this IgM antibody lost much of its ability to bind antigen when coupled to an insoluble matrix. "Second generation" murine monoclonal antibodies and polyclonal rabbit antibodies to purified DU-PAN-2 antigen preparations could result in production of IgG antibodies or antibodies with greater binding affinities to this antigen.
The detection of soluble tumor antigen in ascites and cyst fluids may offer an approach to diagnosis of carcinoma independent of cytologic examination. The number of patients with ascites or cyst fluid samples tested in this report for DU-PAN-2 antigen is small, but impressive differences were noted between the antigen activity in ascites from patients with chronic renal failure or nonepithelial tumors and ascites due to pancreatic carcinoma (Table 1) . There were also quantitative differences between the ascitic fluids from pancreatic tumor patients and some of those from patients with other solid tumors. This suggests that assay of DU-PAN-2 antigen in ascitic fluids of patients with adenocarcinoma may help in determining the primary site of a tumor. We were also able to detect high levels of antigen in pancreatic duct fluids (Table 1 ). Consequently, it is possible to evaluate DU-PAN-2 antigen levels in pancreatic secretion samples taken from a variety of patients during endoscopic cannulation of the pancreatic duct. Since many pancreatic adenocarcinomas are located in the head of the pancreas and often obstruct the pancreatic duct, these secretions may be a good source of material for assays designed to facilitate early detection of a primary tumor. The cyst fluid from the patient with mucinous cystadenocarcinoma ofthe pancreas and some of the ascites from pancreatic cancer patients also have provided enriched sources of antigen for purification and characterization studies.
It is the detection of DU-PAN-2 antigen in serum, however, that is of the greatest potential diagnostic value. Sera from 77% of patients with pancreatic adenocarcinoma, irrespective of therapy or disease status, had increased levels (>300 units/ml) of DU-PAN-2 antigen. Another antigen (CA 19-9), detected by a monoclonal antibody in a radioimmunometric assay, has also been reported to be increased in serum from patients with pancreatic adenocarcinoma (9, 10) . This antigen was shown to be a sialylated lacto-N-fucopentose II epitope that on cell lines and tumor cells is associated with a monosialoganglioside. In serum this antigen occurs as a mucin (9, 10) . Reagent exchanges, specificity studies, and the inability of the 19-9 antibody to immunoblot the DU-PAN-2 antigen indicate that the epitopes and molecules detected by the 19-9 and DU-PAN-2 monoclonal antibodies are different (unpublished data).
The presence of very high levels of antigen (10,000 to 100,000 units/ml) in sera from some pancreatic cancer patients may be a reflection of liver disease, since all of the patients with these high levels had nonresectable liver metastases. Thus, as with carcinoembryonic antigen, the serum levels of the antigen may reflect not only its shedding or release from a given tumor but also the ability of the patient to catabolize the antigen (11) . Elevation of serum DU-PAN-2 antigen is not strictly a reflection of liver disease per se, since some patients with colorectal carcinomas in this study had impaired liver function with normal antigen levels, presumably because their tumors did not express DU-PAN-2 antigen (4).
This initial retrospective serum study does not allow us to correlate DU-PAN-2 antigen levels with the status of disease or liver function since it was not possible to determine the exact tumor burden or have available the bilirubin levels on many of the patients studied. This type of clinical correlation can best be accomplished in a prospective study in which the appropriate clinical and clinical laboratory data can be obtained on the dates when body fluid samples are taken for DU-PAN-2 antigen testing. However, the data from patient B (Table 2 ) suggest that the assay may provide a sensitive indicator for recurrence in a disease that has traditionally been difficult to monitor. The test could be helpful for identifying the origin of tumors with metastases, particularly to the liver. We feel that the clinical applications of the determination of DU-PAN-2 antigen in body fluids is encouraging but that a more comprehensive testing program is warranted.
